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Abstract The cDNA clones of two isoforms (enzymes I and II)
of human placental ecto-ATP diphosphohydrolases have been
isolated based on the N-terminal amino acid (aa) sequence of the
immunopurified 82 kDa protein and characterized. The cDNA
clone encoding enzyme I consists of 2081 nucleotides and the
predicted enzyme I consists of 517 aa residues. Enzyme I has a
5P-UTR and an N-terminal 11 aa sequence that differ from
CD39, but the rest of the sequence is the same as CD39. The
hydropathy plot indicated that enzyme I has two hydrophobic
regions near the N- and C-termini of the molecule. In contrast,
enzyme II consists of 1814 nucleotides and the predicted protein
consists of 306 aa residues. The sequence of 1^1018 nucleotides
of enzyme II is identical to that of enzyme I, but the 1019^1814
nucleotide sequence is different from both enzyme I and CD39.
The hydropathy plot indicated that enzyme II has one hydro-
phobic region near the N-terminus, suggesting that enzyme II is
also anchored to the cell membrane. It is, however, likely that
some of enzyme II exists as a soluble form in plasma, possibly
after proteolytic processing.
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1. Introduction
Ecto-ATP diphosphohydrolases (ATPDases), or ecto-apyr-
ases, are ubiquitous integral membrane proteins that play im-
portant roles in essential biological functions such as apopto-
sis, signal transduction, and hemostasis [1]. Ecto-ATPDases
hydrolyze ATP and ADP to AMP in the presence of Ca2 or
Mg2, and AMP is then converted to adenosine by 5P-nucle-
otidase [1]. ADP is a typical agonist of platelet aggregation,
whereas adenosine is an inhibitor of platelet aggregation [2,3].
Ecto-ATPDases, therefore, function as strong inhibitors of
platelet aggregation through their scavenging e¡ects on en-
dogenous ADP released from the activated platelets in asso-
ciation with adenosine [3].
CD39, initially identi¢ed in activated B-lymphocytes [4], has
been demonstrated to be a vascular ecto-apyrase in humans
from the following evidence. (1) The cDNA sequence of CD39
is partially homologous to that of soluble potato apyrase, and
ATPDase activity appears in Epstein-Barr virus-transformed
B-lymphocytes, which express CD39 on their cell surface [5,6].
(2) The partial internal amino acid (aa) sequences of human
placental ecto-ATPDase closely match the deduced aa se-
quence of CD39 [7], and the enzyme activity also appears in
CD39 cDNA-expressed COS cells [8]. (3) Anti-CD39 murine
monoclonal antibody (mAb) immunoprecipitates the protein
with the simultaneous disappearance of ATPDase activity
from solubilized human umbilical vein endothelial cells (HU-
VECs) [9].
Human placental ecto-ATPDase has been initially reported
to have a blocked N-terminus [7], but recently we have ob-
tained N-terminal 30 residue aa sequence of the highly puri-
¢ed 82 kDa enzyme, prepared by an immunoadsorbent chro-
matography with a speci¢c mAb (MK33, IgG1-U) [10].
Interestingly, the ¢rst 11 residue sequence was di¡erent from
that of CD39, but the following residues 12^30 and partial
sequences derived from the internal regions were the same as
those of CD39 [10]. This suggested that placental ecto-ATP-
Dase is an isoform of CD39. More recently, CD39L1-L4
clones have been isolated from human cDNA libraries, but
without extensive characterization. [11,12]. Further, the
cDNA cloning of human brain ecto-ATPDase has been per-
formed using polymerase chain reaction (PCR) in which query
nucleotide sequences derived from the chicken smooth muscle
ecto-ATPase cDNA were used [13]. These ¢ndings have sug-
gested that human ecto-ATPDases consisted of a family of
CD39s as indicated in non-human ecto-ATPDases [4,11^20].
Based on the protein sequence data obtained with the im-
munopuri¢ed placental ecto-ATPDase, we isolated two
cDNA clones and examined the entire nucleotide sequences
of the two. The protein deduced from enzyme I clone con-
sisted of 517 aa residues and had structural features in accord
with the immunopuri¢ed enzyme, but di¡ered only in the N-
terminal aa sequence from CD39. The other (enzyme II) was
encoded with a nucleotide sequence highly homologous to
that of the enzyme I clone, and consisted of 306 aa residues.
Both enzymes I and II had the putative ATP-binding motif
[20] and the predicted apyrase conserved regions [6] compara-
ble with CD39. The hydropathic plots predicted that enzyme I
had two putative transmembrane sequences in both the N-
and C-terminal regions like CD39, but, unlike CD39, enzyme
II had only one putative transmembrane sequence in the N-
terminal region.
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2. Materials and methods
2.1. N-terminal and internal aa sequences of human placental
ecto-ATPDases
The aa sequences of the N-terminal 30 residues of the immunopuri-
¢ed 82 kDa human placental ecto-ATPDase and of the peptides gen-
erated with Achromobacter protease (AP) I and separated by reversed-
phase high performance liquid chromatography on a C18 column
have already been determined [10] as follows: MKGTKDL-
TSQQKESNVKTFxSKNILAILGF (N-terminus), FVQK (AP 7-1),
DLTSQQK (AP 7-2), GPGISK (AP 8-1), VTEMx (AP 8-2),
TSYAGVK (AP 12), DQALWQK (AP 19), DYNYYTHSFLxYGK
(AP 28), YGIVLDAGGHTSLYIY (AP 29), TRWFSIVPYET
NNQETGETFGALDLGGAxTQVxF (AP 36) (where x indicates an
unidenti¢ed residue).
2.2. Isolation and sequencing of the 5P-terminal partial cDNA
nucleotide, N-300
Human placental cDNA library (Lot 102) was obtained from Ta-
kara Shuzo Co. (Shiga, Japan), and used as a template to conduct
semi-nested PCR. Since the N-terminal 11^30 aa residue sequence of
human placental ecto-ATPDase was completely identical with that of
residues 5^23 of human CD39 [4], the ¢rst PCR was performed using
two primers: the sense primer (T7) with the ¢xed nucleotide sequence
of 5P-TAATACGACTATAGGG-3P corresponding to the £anking T7
promoter region of vector pAP3neo DNA, and the antisense primer
(PL2) of the degenerated nucleotide sequence of 5P-(G/A/T/C)(G/
C)(A/T)(A/G)AA(G/A/T/C)CC(G/A/T/C)A(A/G)(G/A/T)AT(G/A/T/
C)GCA(G/A/T/C)A(A/G)(G/A/T)A-3P corresponding to the aa se-
quence ILAILGF in the N-terminal region. The reaction mixture in-
cluding Ex-Taq polymerase (Takara Shuzo Co.), 1 Wl of human pla-
cental cDNA library, 0.5 WM T7, and 0.5 WM PL2 was heated at 94‡C
for 5 min once, followed by thermal cycling at 94‡C for 30 s, 55‡C for
30 s, and 72‡C for 90 s for 30 cycles, and ¢nally one cycle at 72‡C for
7 min. For the second semi-nested PCR, the two primers used were T7
(sense) and the degenerate primer, 5P-AA(G/A/T/C)GT(C/T)TT(G/A/
T/C)AC(A/G)TT(G/A/T/C)(G/C)(A/T)(C/T)TC-3P (antisense, PL4)
corresponding to the aa sequence ESNVKTF in the N-terminal re-
gion. The second PCR ampli¢ed 1 Wl of a 1:50 dilution of the ¢rst
PCR product using Ex-Taq polymerase, 0.5 WM T7, and 0.5 WM PL4
with the same thermal cycling protocol as that used in the ¢rst PCR.
After the second PCR, only one cDNA band of V300 bp termed
N-300 was obtained. The N-300 band was cut from the gel and pu-
ri¢ed by Geneclean II Kit (Bio 101, California, USA), and then it was
subcloned using TOPO TA cloning kit (Invitrogen, Carlsbad, CA,
USA) for nucleotide sequencing.
2.3. Isolation and sequencing of the residual and 3P-terminal partial
cDNAs, C-1800 and C-1600
The 3P-terminal cDNA sequence of human placental ecto-ATPDase
was determined by the semi-nested PCR using the same library de-
scribed above. The ¢rst PCR was conducted using two ¢xed primers:
5P-TGAAGGGAACCAAGGACCTG-3P (sense, PL18, nucleotides
185^204 of N-300) which was determined as the nucleotide sequence
corresponding to the aa sequence KGTKDL, speci¢c to placental
ecto-ATPDase but not to CD39 (see Section 3), and 5P-TAATAC-
GACTCACTATAGGG-3P (antisense, T3, corresponding to the se-
quence speci¢c to the £anking T3 promoter region of the vector).
The ¢rst PCR was performed using Ex-Taq polymerase, 1 Wl of the
human placental cDNA library, 0.5 WM T3, and 0.5WM PL18. The
reaction mixture was subjected to a thermal cycling process as already
described. The second semi-nested PCR ampli¢ed 1 Wl of a 1:50 di-
lution of the ¢rst PCR product using Taq polymerase, 0.5 WM T3
(antisense), and 0.5 WM PL19 (sense, 5P-GAAGGGAACCAAG-
GACCTGA-3P, a gene-speci¢c 186^205 nucleotide sequence of N-
300). The thermal cycling protocol of the second PCR was the same
as that used in the ¢rst PCR. After the second PCR, the two partial
cDNA bands with di¡erent sizes ofV1800 bp andV1600 bp, termed
C-1800 and C-1600 fragments, were detected using agarose gel electro-
phoretic analysis. Both the partial cDNA bands were cut from the gel
separately, and were then independently subcloned for nucleotide se-
quencing.
2.4. DNA sequencing and database analysis
DNA sequencing was performed with an automated ABI-Prism 310
Genetic Analyzer. Both the DNA and deduced protein sequences were
compared with sequences in the GenBank, Swiss-Prot or PIR data-
bases using BLAST programs [21].
2.5. Detection of enzyme I, II and CD39 in placenta and HUVEC
cDNA libraries by PCR
To examine the tissue-speci¢c localization of enzyme I, II and
CD39, PCR was conducted using placenta and HUVEC cDNA libra-
ries as the templates. For this, two nucleotide sequences of sense and
antisense primers complementary to the determined N- and C-termi-
nal aa sequences of the respective cDNAs were used as shown in Fig.
4.
The reaction mixture including Taq polymerase, 1 Wl of human
placenta or HUVEC V-ZAP (kindly provided by Dr. Toshiyuki Miya-
ta of the Research Institute, National Cardiovascular Center, Osaka,
Japan) cDNA library, 0.5 WM sense primer, and 0.5 WM antisense
primer was subjected to PCR using the same thermal cycling process.
The ampli¢ed PCR products were separated on 1% agarose gel elec-
trophoresis in the presence of ethidium bromide and visualized under
UV light.
2.6. Northern analysis using enzyme II-speci¢c probe in placenta
For placental mRNA analysis, Northern Territory mRNA blots, a
charge-modi¢ed nylon membrane to which poly(A) RNA (2 Wg per
lane) from human placenta had been transferred, was used (Invitro-
gen, Carlsbad, CA, USA). The enzyme II-speci¢c probe was generated
from the placental cDNA library by PCR using two primers, PL43
(sense) and PL30 (antisense) as shown in Fig. 5. The PCR was per-
formed using Ex-Taq polymerase, 1 Wl of the human placental cDNA
library, 0.5 WM PL43, and 0.5WM PL30. The reaction mixture was
heated at 94‡C for 5 min once, then heated to 94‡C for 30 s, 55‡C for
30 s, and 72‡C for 30 s for 30 cycles, and ¢nally one cycle at 72‡C for
7 min. The ampli¢ed PCR products were separated by 1% agarose gel
electrophoresis in the presence of ethidium bromide and visualized
under UV light. The fragment (482 bp) for the enzyme II-speci¢c
probe was puri¢ed with the Geneclean II kit and labeled with Bright-
Star psoralen-biotin non-isotonic ;abeling Kit (Ambion, Austin, TX,
USA). Prehybridization and hybridization were carried out following
the manufacturer’s instructions of Northern Territory mRNA blots.
And the detection procedure was carried out with BrightStar BioDe-
tect non-isotonic detection kit (Ambion). The blot was exposed to a
Kodak scienti¢c imaging ¢lm (Eastman Kodak Company, Rochester,
NY, USA) for 20 h.
3. Results and discussion
Nucleotide sequencing revealed that the 5P-terminal cDNA
fragment (N-300) was composed of 239 bp, and the aa se-
quence deduced from the internal 184^237 nucleotide se-
quence (Fig. 1, shaded bar) completely matched the N-termi-
nal 1^18 residue sequence (MKGTKDLTSQQKESNVKT) of
human placental ecto-ATPDase [10], but di¡ered from that of
human CD39 [4]. The ¢rst 183 nucleotides appeared to encode
5P-UTR, because no signi¢cant propeptide cleavage site was
found using the PSORT program [22], and in addition, this
nucleotide sequence was also completely di¡erent from that of
CD39. After determination of the nucleotide sequence of N-
300, the cDNA sequence(s) encompassing the residual and 3P-
terminal portions were determined using semi-nested PCR
ampli¢cation, in which the ¢rst PCR was performed using
the sense primer, PL18 (5P-TGAAGGGAACCAAG-
GACCTG-3P, corresponding to nucleotides 185^204) and
the antisense primer, T3 (5P-TAATACGACTCACTATAGG
G-3P, speci¢c to the £anking region of the vector), and the
second PCR used PL19 (sense, 5P-GAAGGGAACCAAG-
GACCTGA-3P, corresponding to nucleotides 186^205) and
the antisense primer of T3 common to the ¢rst PCR. After
the second PCR ampli¢cation, two distinct cDNA fragments,
termed C-1800 and C-1600, were obtained, and the following
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subcloning and nucleotide sequencing revealed that C-1800
was composed of 1895 bp, whereas C-1600 was 1628 bp.
The 5P-terminal ¢rst 54 nucleotide sequences were identical
to each other and overlapped with the nucleotide sequence
187^239 of N-300. A stop codon was identi¢ed at nucleotides
1735^1737 (TAG) for C-1800, and at nucleotides 1101^1104
(TAG) for C-1600. To address whether a pair of N-300 and
C-1800 or N-300 and C-1600 came from the same cDNAs, 5P-
terminal nucleotide sequences were determined by PCR using
two sets of primers each of which was speci¢c to enzyme I and
II. A pair of primers T7 (sense) and PL24 (antisense, shown in
Fig. 4) for enzyme I and of primers T7 (sense) and PL32
(antisense, shown in Fig. 4) for enzyme II were used. The
nucleotide sequencing of these two PCR products con¢rmed
Fig. 1. The cDNA sequence and the deduced amino acid sequence
of human placental ecto-ATPDase (enzyme) I. The entire cDNA se-
quence of enzyme I was determined by analysis of two partial
cDNAs, N-300 (nucleotides 1^239) and C-1800 (nucleotides 186^
2081) as described in Section 3. The shaded area indicates the N-
terminal 30 aa sequence determined by protein sequencing [10]. The
putative ATP-binding domain [6] is enclosed, and the putative apyr-
ase conserved regions [20] are underlined. The potential N-glycosyla-
tion sites are indicated by asterisks. The position of the termination
(stop) codon is indicated by a circle.
Fig. 2. The cDNA sequence and the deduced amino acid sequence
of human placental ecto-ATPDase (enzyme) II. The entire cDNA
sequence of enzyme II was determined by analysis of two partial
cDNAs, N-300 (nucleotides 1^239) and C-1600 (nucleotides
186W1814) as described in Section 3. The putative ATP-binding do-
main [6] is enclosed, and the putative apyrase conserved regions [20]
are underlined. Potential N-glycosylation sites are indicated by aster-
isks. The position of the termination (stop) codon is indicated by a
circle. The shaded area indicates 28 aa residue sequences which can-
not be identi¢ed in enzyme I.
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that each set of N-300 and C-1800 or N-300 and C-1600
originated from similar but independent cDNAs (data not
shown). The full-length cDNAs and the deduced aa sequences
of two isoforms of human placental ecto-ATPDases (enzyme I
and II) are shown in Figs. 1 and 2. The cDNA of enzyme I
consisted of 2081 nucleotides which include 183 bp of 5P-
UTR, 1551 bp of ORF, a stop codon and 344 bp of 3P-
UTR, and the aa residues were predicted to be 517. In com-
parison of the aa sequences, enzyme I only di¡ered from
CD39 in the N-terminal region, indicating that they were gen-
erated by alternative splicing at the pre-mRNA level. An en-
tirely di¡erent structure in the 5P-UTR cDNA of enzyme I
and CD39 also supports this speculation. The molecular mass
of enzyme I was calculated to be 58 706 Da based on the
backbone aa sequence. It contained six potential N-glycosyla-
tion sites, and the pI was estimated to be 6.29 by ExPASY
Fig. 3. Hydropathy plot of human placental ecto-ATPDases (enzymes) I and II. Hydropathy plots using the Sosui program indicate that en-
zyme I has two hydrophobic regions near the N- (aa residues 22^44) and C-termini (aa residues 485^507), and enzyme II has only one hydro-
phobic region near the N-terminus (aa residues 22^44). The hydrophobic regions, which may be potential membrane-spanning regions, are en-
closed.
Fig. 4. Agarose gel analysis of PCR products with a pair of primers speci¢c to placental ecto-ATPDases (enzymes) I, II, and CD39, using pla-
centa and HUVEC cDNA libraries. In the left panel, the primer design used in this study is shown. The black bars indicate identical regions in
the three enzymes. From the placenta cDNA library, each single band with V1550 bp for enzyme I, V884 bp for enzyme II, or V1530 bp of
CD39 was detected. From the HUVEC library, one band with V1530 bp of CD39 was detected, but no band relevant to enzyme I was ob-
served. Further, for enzyme II some bands were also detected in addition to the V884 bp band. The expected bands are shown by the arrows.
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server [23]. These structural features were in accord with those
of the immunopuri¢ed placental ecto-ATPDase [10]. Further-
more, the hydropathy plot using the SOSUI program [24]
indicated that enzyme I had two hydrophobic regions in the
molecule (Fig. 3, top), suggesting that enzyme I was anchored
to the cell surface of placental syncytiotrophoblasts in the N-
and C-terminal regions, in a manner similar to CD39.
In contrast, enzyme II consisted of 1814 nucleotides which
included 183 bp of 5P-UTR, 918 bp of ORF, a stop codon and
710 bp of 3P-UTR. Thus, the deduced enzyme II consisted of
306 residues with a molecular mass of 34 175 Da. It had an
estimated pI of 6.45, and contained two potential N-glycosyl-
ation sites by ExPASY server. The sequence of nucleotides
1^1018 of enzyme II is totally identical to that of enzyme I,
but the 1019^1814 nucleotide sequence was quite di¡erent
from both enzyme I and CD39. The predicted C-terminal aa
sequence of enzyme II is ASITQSRPAPFTSAPPAPTSC-
CFLFQIQ, and no homologous protein to this sequence
was found by BLAST search. Hydropathy plot indicated
that enzyme II had one hydrophobic region near the N-termi-
nus, which may be the transmembrane domain (Fig. 3, bot-
tom).
We have previously shown that placental ecto-ATPDase
localizes on microvillous syncytiotrophoblasts and umbilical
veins but not on umbilical arteries using the speci¢c murine
mAb MK33. However, this distribution was indistinguishable
by the use of anti-human CD39 mAb [10]. Since the entire
cDNA sequences of placental ecto-ATPDases were elucidated
here, we examined the tissue speci¢city of enzyme I, II, and
CD39 by PCR using placenta and HUVEC cDNA libraries as
the templates. A pair of primers speci¢c to the respective
cDNAs are shown on the left of Fig. 4. When placenta
cDNA was used as a template, the results were clear because
each PCR product gave one band with the estimated size of
nucleotides (Fig. 4). In addition, when HUVEC cDNA was
used, a PCR band representing CD39 was clearly detected,
but that of enzyme I was missing. More interestingly, in the
HUVEC cDNA library, several PCR bands, including enzyme
II seen in the placenta cDNA library, were detected (Fig. 4).
Taking these ¢ndings together, both enzyme I and CD39 ap-
pear to be membrane-bound proteins and structurally similar
to each other, but they localize separately.
Of particularly interest is enzyme II, because this enzyme is
not immunopuri¢ed by mAb MK33, but the protein sequence
deduced from its cDNA indicates the presence of a putative
ATP-binding domain (aa residues 59^65) and ‘apyrase con-
served regions’ (aa residues 63^68, 131^132, 137^142, 178,
182^183, 190, 220, and 222^227) common to enzyme I and
CD39. To demonstrate the evidence for the existence of en-
zyme II, we analyzed mRNA puri¢ed from human placenta
by hybridization with the enzyme II-speci¢c probe (482 bp).
We found a message for enzyme II in approximately 1800 bp,
identical to enzyme II in size, and several other messages in a
high bp region. Several di¡erent mRNA transcripts reacting
with the enzyme II-speci¢c probe seem to be multiple RNA
transcripts probably by alternative splicing. Similar results of
Northern analysis in CD39 were reported by Kaczmarek et al.
[8].
One of the reasons why enzyme II is not immunopuri¢ed
may be explained by a lack of the epitope of mAb MK33,
because this mAb was raised against enzyme I. Another pos-
sibility may be the much more reduced expression of enzyme
II than enzyme I in placental microvilli. A speculation that
enzyme II may be proteolytically more cleavable than enzyme
I is also possible, and thus it may exist as soluble ATPDase in
plasma during normal pregnancy [25,26]. Since we have
shown that the placental ecto-ATPDase functions as a potent
inhibitor not only for agonist-induced platelet aggregation but
also for shear-induced platelet aggregation [10], the enzyme(s)
particularly in its soluble form may participate in anti-throm-
botic functions in normal pregnancy with a hypercoagulable
state.
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